<DOC>
	<DOCNO>NCT00338650</DOCNO>
	<brief_summary>The primary objective study make adalimumab available patient suffer moderately severely active Crohn 's Disease fail respond , lose response , intolerant infliximab , evaluate safety</brief_summary>
	<brief_title>Treatment Human Anti-TNF Monoclonal Antibody Adalimumab Moderate Severe Crohn 's Disease With Previous Exposure Infliximab ( CHOICE )</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patient diagnose moderate severe Crohn 's Disease . Failed prior infliximab therapy . Patient judge generally good health determine principal investigator . Previous treatment adalimumab . Patient consider investigator , reason , unsuitable candidate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>